Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical stage biotech company focusing on developing melanocortin receptor based therapeutics, the analyst tells investors in a research note. The firm believes the company’s offerings are better than Rhythm Pharmaceuticals’ (RYTM) setmelanotide and are very competitive against their next generation follow-on products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTN: